



**Resonance Health Ltd**  
**ASX / Media Release**

**2 June 2014**

---

## Clarification Statement

Resonance Health Limited (ASX: RHT) remains in a trading halt until Tuesday 3<sup>rd</sup> June.

The Entitlement Offer to RHT shareholders has been extended to Friday 13<sup>th</sup> June.

Deferred settlement shares RHTN remain in suspension until 16<sup>th</sup> June. RHTN is only a temporary code used to transition rights issued shares into ordinary RHT shares.

If any shareholder has any questions regarding these matters, please contact Adrian Bowers.

Adrian Bowers  
Company Secretary  
T: +61 8 9286 5300  
E: [adrianb@resonancehealth.com](mailto:adrianb@resonancehealth.com)

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.